MedTrace Logo

COVID-19 Vaccination in Rheumatic Disease Patients

NCT04839315 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2022-06-03

No results posted yet for this study

Summary

The research is being done to study the immune responses to COVID-19 vaccination in patients with rheumatic diseases.

Conditions

Interventions

BIOLOGICAL

mRNA COVD19 vaccine

Subjects will receive two doses of mRNA based COVID19 vaccines.

Sponsors & Collaborators

Principal Investigators

  • Hu Zeng, PhD · Mayo Clinic

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-15
Primary Completion
2022-02-09
Completion
2022-02-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04839315 on ClinicalTrials.gov